Clinical Trial Update: Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lenabasum for diffuse cutaneous systemic sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• lenabasum (lenabasum)

Snippet

Sponsor: Corbus Pharmaceuticals Inc. | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 3 | Status: TERMINATED